Dave Mott, president and chief executive officer (CEO) of AstraZeneca’s (London, UK) biologics business unit, MedImmune (Gaithersburg, MD), has decided to leave the company at the end of July.
Dave Mott, president and chief executive officer (CEO) of AstraZeneca’s (London, UK) biologics business unit, MedImmune (Gaithersburg, MD), has decided to leave the company at the end of July. Tony Zook, CEO of AstraZeneca’s North American business and executive vice president of global marketing, has been appointed as head of MedImmune on an interim basis until a permanent successor is identified.
